People: Hemispherx Biopharma, Inc (HEB)

William.A. Carter, M.D., is Chairman of the Board, Chief Executive Officer of Hemispherx Biopharma Inc. He is the coinventor of Ampligen®, joined Hemispherx Biopharma Inc. in 1978, and has served as: (a) the company's Chief Scientific Officer since May 1989; (b) the Chairman of the company's Board of Directors since January 1992; (c) the company's Chief Executive Officer since July 1993; (d) the company's President since April, 1995; and (e) a director since 1987. From 1987 to 1988, Dr. Carter served as the company's Chairman. Dr. Carter was a leading innovator in the development of human interferon for a variety of treatment indications including various viral diseases and cancer. Dr. Carter received the first FDA approval to initiate clinical trials on a beta interferon product manufactured in the U.S. under his supervision. From 1985 to October 1988, Dr. Carter served as the company's Chief Executive Officer and Chief Scientist. He received his M.D. degree from Duke University and underwent his postdoctoral training at the National Institutes of Health and Johns Hopkins University. Dr. Carter also served as Professor of Neoplastic Diseases at Hahnemann Medical University, a position he held from 1980 to 1998. Dr. Carter served as Director of Clinical Research for Hahnemann Medical University's Institute for Cancer and Blood Diseases, and as a professor at Johns Hopkins School of Medicine and the State University of New York at Buffalo. Dr. Carter is a Board certified physician and author of more than 200 scientific articles, including the editing of various textbooks on anti-viral and immune therapy.